Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;53(4):469-473.
doi: 10.1111/cea.14284. Epub 2023 Jan 17.

Glucagon-like peptide-1 receptor agonist use is associated with lower serum periostin

Dinah Foer  1   2   3 , Patrick E Beeler  2   3   4   5 , Jing Cui  2   6 , William E Snyder  7 , Mona Mashayekhi  7 , Hui Nian  8 , James M Luther  9   10 , Elizabeth W Karlson  2   6 , Joshua A Boyce  1   2 , Katherine N Cahill  11
Affiliations

Glucagon-like peptide-1 receptor agonist use is associated with lower serum periostin

Dinah Foer et al. Clin Exp Allergy. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

D.F., P.E.B., J.C., W.E.S., M.M., H.N., E.W.K., have no relevant conflicts of interest to disclose. J.M.L. has served on scientific advisory board for Mineralys and consulted for Bayer, unrelated to the submitted work. J.A.B. has served as a scientific advisory board member for Sanofi-Regeneron, Third Harmonic Bio, and Siolata Therapeutics, unrelated to the submitted work. K.N.C. has served on scientific advisory boards for Novartis, GlaxoSmithKline, Regeneron, and Sanofi and reports personal fees from Third Harmonic Bio, Ribon Therapeutics, and Verantos and research funding from the National Institutes of Health (U01AI155299) and research support in the form of investigational product from Novo Nordisk outside the submitted work.

Figures

Figure 1.
Figure 1.
Change in serum periostin from baseline to 2 weeks [−3.23 (95% CI, −5.79 to −0.67)] and to 14 weeks [−2.87, (95% CI, −5.75 to 0.00)] in patients randomized to liraglutide (glucagon-like peptide-1 receptor agonist, GLP-1RA; N=41 available samples), sitagliptin (dipeptidyl peptidase-4 inhibitor, DPP-4i; N=22 available samples), or hypocaloric diet (N=17 available samples). Liraglutide dosing was 0.6 mg/d for one week, 1.2 mg/d for one week, then 1.8 mg/d subcutaneously. Sitagliptin was dosed at 100 mg/d. Median and 95% confidence interval reported for each time point. P-values are based on the Wilcoxon signed-rank test. ** P<0.01, *P<0.05
See this image and copyright information in PMC

References

    1. Wu AY, Cahill KN, Toki S, Peebles RS Jr. Evaluating the glucagon-like peptide-1 receptor in managing asthma. Current opinion in allergy and clinical immunology. 2022;22(1):36–41. Epub 2021/11/14. doi: 10.1097/aci.0000000000000797. - DOI - PMC - PubMed
    1. Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma Exacerbations in Type 2 Diabetics with Asthma on Glucagon-like Peptide-1 Receptor Agonists. American journal of respiratory and critical care medicine. 2020. doi: 10.1164/rccm.202004-0993OC. Online ahead of print. Epub 2020/10/15. doi: 10.1164/rccm.202004-0993OC. - DOI - PMC - PubMed
    1. Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, et al. Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. Am J Respir Cell Mol Biol. 2016;55(6):804–14. Epub 2016/07/23. doi: 10.1165/rcmb.2015-0311OC. - DOI - PubMed
    1. López-Cano C, Ciudin A, Sánchez E, Tinahones FJ, Barbé F, Dalmases M, et al. Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study. Diabetes. 2022;71(2):315–20. Epub 2021/11/06. doi: 10.2337/db21-0688. - DOI - PubMed
    1. Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O’Connell J, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57(4):781–4. Epub 2013/12/24. doi: 10.1007/s00125-013-3145-0. - DOI - PubMed

Publication types

Substances